Regulatory PathRegulatory requirements compared

Active substance

Glucose

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
GLUCOSE 10% INF.10 %Intravenous infusion · Intravenous use1 BagSAR 5.35Generic · PrescriptionQATAR PHARMAWithdrawn by regulatory authority · Not Marketed
GLUCOSE 10% INF.10 %Intravenous infusion · Intravenous use1 BottleSAR 4.45Generic · PrescriptionQATAR PHARMAWithdrawn by regulatory authority · Not Marketed
GLUCOSE 5% W/V INTRAVENOUS Infusion*5 %Intravenous infusion · Intravenous use1 BagSAR 4.50Generic · PrescriptionSMSCOSuspended · Not Marketed

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
NHS Drug TariffGlucose 40% oral gel£7.1675 gram1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

WHO WHO Model List of Essential Medicines (2025)

  • 26.2. Solutions correcting water, electrolyte and acid-base disturbances > Parenteral · core
    Hypoglycaemia without associated diabetes; Other specified disorders of fluid, electrolyte or acid-base balance
    Parenteral > General injections > IV: 50% hypertonic | Parenteral > General injections > IV: 5% isotonic; 10% hypertonic

Combinations containing Glucose

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.